# Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

> **NCT00402558** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Leukemia

## Interventions

- **DRUG:** Thymoglobulin
- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **PROCEDURE:** Alloreactive NK Infusion
- **DRUG:** G-CSF
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT00402558
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402558, "Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00402558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*